French Robotics Firm Wandercraft Raises €64.3 Million In Series D Round

The round saw support from major backers including Renault Group, Bpifrance, the European Investment Bank, Teampact Ventures, Quadrant Management, LBO France, Mutuelles Impact (managed by XAnge), Cemag Invest, Martagon Capital, and AG2R LA MONDIALE.

“The momentum we’ve achieved over the past few years is extraordinary,” said Matthieu Masselin, CEO and Co-founder of Wandercraft. “We’ve expanded globally, launched pivotal clinical trials, readied the commercialisation of Eve, our personal exoskeleton, and entered a landmark partnership with Renault. This funding allows us to continue our mission of transforming how people live, move, and work across rehabilitation, home environments, and soon on factory floors.”

With new funding in hand, the company plans to expand beyond clinical settings into consumer and industrial markets, aiming to bring advanced mobility solutions into homes and workplaces.

Wandercraft is also preparing to launch Eve by 2026—the world’s first self-balancing personal exoskeleton. Designed for people with severe mobility impairments, Eve enables upright movement without the need for crutches or walkers.

Read Also - Arlequin AI Funding News -Paris-based Arlequin AI Secures €4.4 Million In Seed Round

It’s powered by AI and has been developed through billions of simulations and tens of millions of real-world steps.

Eve is currently in pivotal clinical trials and has already been part of the first-ever study on using a self-balancing personal exoskeleton in home and community environments.

Renault Group has become both a strategic investor in Wandercraft and the first commercial customer for its industrial humanoid robot, Calvin-40. Built in just 40 days—hence the name—Calvin-40 is designed to handle demanding factory tasks and will begin production within 40 weeks at Renault’s facilities.

Developed using Wandercraft’s proprietary robotics platform and advanced through a collaboration with NVIDIA, Calvin-40 highlights the potential for rapidly deployable, industrial-grade robotics in Europe.

This partnership is expected to help scale both the Eve and Calvin product lines by leveraging Renault’s manufacturing capabilities to bring robotic mobility solutions to more markets.

Meanwhile, Wandercraft’s clinical division continues to expand, especially in the U.S., following a €39.2 million Series C round that supported the launch of its first U.S. walk center in New York City and fueled a tenfold increase in revenue.

The company’s clinical exoskeleton, Atalante X, has received two FDA clearances for stroke rehabilitation and is being used at top institutions like the Kessler Foundation in the U.S. and Vivantes Klinikum Spandau in Germany.

Backed by more than 20 clinical studies, Atalante X has helped over 2,500 users take more than 14 million steps, showing measurable gains in gait, balance, and muscle strength.

Wandercraft is now set to push the boundaries of robotic mobility further—restoring movement for those with disabilities and reshaping how people work in industrial environments.

About Wandercraft

Founded in 2012, Wandercraft is a pioneer in robotic mobility, best known for its clinical exoskeleton, Atalante X, which is now used in over 100 hospitals and rehabilitation centers worldwide.